
Does Elinzanetant Reduce VMS in Younger Patients?
Another phase 3 trial has demonstrated the effectiveness of the dual-neurokinin receptor antagonist elinzanetant in controlling hot flashes in women on adjuvant endocrine therapy for hormone receptor-positive (HR+) breast cancer. This time, the sample …